» Articles » PMID: 30774276

Hepatocellular Carcinoma: Can LI-RADS V2017 with Gadoxetic-acid Enhancement Magnetic Resonance and Diffusion-weighted Imaging Improve Diagnostic Accuracy?

Overview
Specialty Gastroenterology
Date 2019 Feb 19
PMID 30774276
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Liver Imaging Reporting and Data System (LI-RADS), supported by the American College of Radiology (ACR), has been developed for standardizing the acquisition, interpretation, reporting, and data collection of liver imaging examinations in patients at risk for hepatocellular carcinoma (HCC). Diffusion-weighted imaging (DWI), which is described as an ancillary imaging feature of LI-RADS, can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance imaging (MRI) for HCC.

Aim: To determine whether the use of DWI can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance MRI for HCC.

Methods: In this institutional review board-approved study, 245 observations of high risk of HCC were retrospectively acquired from 203 patients who underwent gadoxetic acid-enhanced MRI from October 2013 to April 2018. Two readers independently measured the maximum diameter and recorded the presence of each lesion and assigned scores according to LI-RADS v2017. The test was used to determine the agreement between the two readers with or without DWI. In addition, the sensitivity (SE), specificity (SP), accuracy (AC), positive predictive value (PPV), and negative predictive value (NPV) of LI-RADS were calculated. Youden index values were used to compare the diagnostic performance of LI-RADS with or without DWI.

Results: Almost perfect interobserver agreement was obtained for the categorization of observations with LI-RADS ( value: 0.813 without DWI and 0.882 with DWI). For LR-5, the diagnostic SE, SP, and AC values were 61.2%, 92.5%, and 71.4%, respectively, with or without DWI; for LR-4/5, they were 73.9%, 80%, and 75.9% without DWI and 87.9%, 80%, and 85.3% with DWI; for LR-4/5/M, they were 75.8%, 58.8%, and 70.2% without DWI and 87.9%, 58.8%, and 78.4% with DWI; for LR- 4/5/TIV, they were 75.8%, 75%, and 75.5% without DWI and 89.7%, 75%, and 84.9% with DWI. The Youden index values of the LI-RADS classification without or with DWI were as follows: LR-4/5: 0.539 0.679; LR-4/5/M: 0.346 0.467; and LR-4/5/TIV: 0.508 0.647.

Conclusion: LI-RADS v2017 has been successfully applied with gadoxetate-enhanced MRI for patients at high risk for HCC. The addition of DWI significantly increases the diagnostic efficiency for HCC.

Citing Articles

Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.

Lee S, Kim Y, Shin J, Shin H, Sirlin C, Chernyak V Eur Radiol. 2024; 34(11):7025-7040.

PMID: 38809263 DOI: 10.1007/s00330-024-10813-5.


Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Alareer H, Arian A, Fotouhi M, Taher H, Abdullah A J Biomed Phys Eng. 2024; 14(1):5-20.

PMID: 38357604 PMC: 10862115. DOI: 10.31661/jbpe.v0i0.2211-1562.


Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment.

Brusset B, Jacquemin M, Teyssier Y, Roth G, Sturm N, Roustit M JHEP Rep. 2024; 6(1):100957.

PMID: 38234407 PMC: 10792651. DOI: 10.1016/j.jhepr.2023.100957.


Liver Imaging Reporting and Data System (LI-RADS) v2018: differential diagnostic value of ADC values for benign and malignant nodules with moderate probability (LR-3).

Chen X, Cai Q, Xia J, Huang H, Li Z, Song K Front Oncol. 2023; 13:1186290.

PMID: 37675222 PMC: 10478080. DOI: 10.3389/fonc.2023.1186290.


Magnetic Resonance Imaging for Monitoring of Hepatic Disease Induced by Ebola Virus: a Nonhuman Primate Proof-of-Concept Study.

Lee J, Calcagno C, Feuerstein I, Solomon J, Mani V, Huzella L Microbiol Spectr. 2023; 11(3):e0353822.

PMID: 37184428 PMC: 10269877. DOI: 10.1128/spectrum.03538-22.


References
1.
Lim S, Kim Y, Park H, Lee W, Choi D, Park M . Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T. J Magn Reson Imaging. 2013; 39(5):1238-45. DOI: 10.1002/jmri.24265. View

2.
Komatsu N, Motosugi U, Maekawa S, Shindo K, Sakamoto M, Sato M . Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. Hepatol Res. 2014; 44(13):1339-46. DOI: 10.1111/hepr.12309. View

3.
Reataza M, Imagawa D . Advances in managing hepatocellular carcinoma. Front Med. 2014; 8(2):175-89. DOI: 10.1007/s11684-014-0332-4. View

4.
Chavhan G, Alsabban Z, Babyn P . Diffusion-weighted imaging in pediatric body MR imaging: principles, technique, and emerging applications. Radiographics. 2014; 34(3):E73-88. DOI: 10.1148/rg.343135047. View

5.
Roth C, Mitchell D . Hepatocellular carcinoma and other hepatic malignancies: MR imaging. Radiol Clin North Am. 2014; 52(4):683-707. DOI: 10.1016/j.rcl.2014.02.015. View